Project Grant R01DK138929
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $829,985 Project Grant to the University of Virginia, effective July 1, 2025 through April 30, 2030, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research initiative focuses on developing novel Drosophila, mouse, and human podocyte models to investigate the interaction between HIV genes and APOL1-G1 risk alleles in the...
- This federal Project Grant award of $1,442,061.00, awarded on April 1, 2024 by the Defense Health Agency, supports research under the Military Medical Research and Development program (CFDA 12.420) to investigate the role of podocyte ceramide synthase 6 in focal segmental glomerulosclerosis (FSGS). The primary awardee, the University of Texas Health Science Center at San Antonio, will conduct basic, translational, and clinical research to determine how genetic and toxin-induced FSGS affects...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Washington University a $1.49 million Project Grant effective September 5, 2025, through September 4, 2029, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This award supports basic biomedical research investigating the molecular mechanisms underlying the progression from acute kidney injury (AKI) to chronic kidney disease...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant totaling $109,076.00 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Weill Medical College of Cornell University, effective July 1, 2025, through July 8, 2029. The award supports research focused on pharmacological inhibition of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) as a therapeutic...
- Federal Project Grant Award Summary Rush University Medical Center received a $783,899 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 15, 2026, with completion targeted for November 30, 2030. The award funds research investigating the mechanisms underlying non-HIV collapsing glomerulopathy (CG), a severe form of glomerular...
- Federal Project Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $166,740 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective August 1, 2025, through July 31, 2030. The award funds research investigating the contribution of urinary phosphate to chronic kidney disease (CKD) progression, addressing a...
- Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded University of Colorado-Denver a $117,000 Project Grant on February 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support basic biomedical research on diabetic neuropathy. The project, which extends through January 31, 2028, focuses on identifying extracellular vesicle (EV)-derived protein biomarkers of peripheral nervous system...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Trustees of Columbia University in the City of New York $859,998 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on January 23, 2026, with a completion date of December 31, 2029. This project grant funds research to understand kidney failure mechanisms in individuals with DiGeorge Syndrome (DGS), a rare microdeletion disorder...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of California, San Francisco a $176,244 Project Grant (CFDA 93.847: Diabetes, Digestive, and Kidney Diseases Extramural Research) effective June 15, 2025, with completion scheduled for March 31, 2030. This mentored research and training award supports Dr. Gabriel Loeb's five-year career development plan to establish an independent academic research program focused on...
- Grant Award Summary The University of North Texas Health Science Center at Fort Worth received a $532,177 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025 through June 30, 2029. The research project investigates a novel inflammation pathway in diabetic kidney disease (DKD), the leading cause of end-stage renal disease. The study...
The University of Colorado-Denver received a $394,296 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for research examining podocyte acetylcholine as a potential novel treatment for focal segmental glomerulosclerosis (FSGS). The grant, awarded March 1, 2026, with completion scheduled for November 30, 2029, funds basic and translational research aimed at understanding the mechanisms by which local acetylcholine synthesis in kidney podocytes provides cellular protection against kidney injury in primary FSGS, the most common primary glomerular disorder causing end-stage kidney disease with disproportionately high incidence rates in African Americans. The research deliverables under this award include mechanistic investigations using transgenic mouse models expressing choline acetyltransferase (ChAT), the sole enzyme responsible for acetylcholine production, along with in vitro studies using cultured podocytes to elucidate acetylcholine's role in preserving podocyte actin cytoskeleton integrity and protecting against kidney injury. The project will test the hypothesis that podocyte-derived acetylcholine functions as a self-defense mechanism against FSGS-related damage and explore the therapeutic potential of currently available commercial drugs that increase ChAT expression and acetylcholine production in podocytes, with the ultimate goal of identifying novel treatment approaches for this serious kidney disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $394.3k | 2/27/26 |